+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Implantable Ports - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292438
The implantable ports market size was valued at USD 1.18 billion in 2026 and is estimated to grow from USD 1.30 billion in 2027 to reach USD 2.04 billion by 2032, at a CAGR of 9.53% during the forecast period (2027-2032). This report is Segmented by Product Type (Single-Lumen Implantable Ports, and More), Port Type (Standard Implantable Ports, and More), Material (Titanium, Polyurethane and Polymer, and More), Application (Chemotherapy and Oncology Delivery, and More), End User (Hospitals and Acute Care Facilities, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Implantable Ports Market Trends and Insights

Rising Cancer Incidence and Chemotherapy Administration

The implantable ports market is closely linked to the rising number of patients receiving systemic cancer therapy. IARC reported 20.6 million new cancer cases worldwide in 2024, with lung, breast, and colorectal cancers accounting for the largest portions of diagnosed disease. A 2026 analysis covering 17 cancers across 186 countries estimated 13.58 million diagnosed cases in 2025 and projected 19.32 million by 2050. Growth is expected to be strongest in low- and middle-income countries, where access to diagnosis and systemic treatment is widening. As treatment regimens involve repeated cycles, clinicians need access devices that support dependable drug delivery without repeated peripheral needle placement. The implantable ports market, therefore, benefits as oncology systems in Asia and Latin America add capacity. These conditions also create an opening for domestic manufacturers that can offer cost-competitive devices and establish relationships with local cancer centers.

Growing Geriatric and Chronic-Disease Treatment Burden

The aging population adds patients who often require prolonged intravenous nutrition, antibiotics, transfusions, or cancer treatment. A 2026 study of older adults receiving long-term total parenteral nutrition found that implanted central venous access ports had a median dwell time of 305 days. The same study associated non-tunneled central venous catheters with higher mortality than implanted ports in the study population. Older patients may need vascular access over a longer period because several conditions can be managed at the same time. Osteomyelitis, inflammatory bowel disease, and home parenteral nutrition extend use beyond oncology. The implantable ports market also gains from recurring demand for access needles, flush kits, and dressing products during the device life cycle. This favors manufacturers that can provide both the implanted device and the supplies used to maintain it.

Port- and Catheter-Related Infection and Thrombosis

Infection and thrombosis continue to limit adoption where port placement and maintenance practices are inconsistent. The supplied research states that central line-associated bloodstream infection affects 3% to 10% of port users. A 2025 retrospective study of 867 patients reported an overall bloodstream infection incidence of 13.5% among port users. Lipid emulsion administration and inflammatory bowel disease were independent risk factors in that study. A separate 2025 study reported that an artificial intelligence-based model could help identify patients at higher risk of totally implantable venous access device infection. The implantable ports market consequently places greater value on antimicrobial coatings, antithrombogenic materials, and institutional infection-control practices. Commodity suppliers may find it harder to compete when hospital procurement teams require evidence that a device can support lower complication risk.

Other drivers and restraints analyzed in the report include:
  • Increasing Preference for Long-Term Fully Implanted Vascular Access
  • Expansion of Outpatient and Home-Based Infusion Therapy
  • Surgical Implantation Cost and Procedure Complexity

Segment Analysis

Single-Lumen Implantable Ports held 68.93% of 2026 revenue, giving this format the largest implantable ports market share within the product type segmentation. Their position reflects clinical familiarity and wide use in standard chemotherapy and total parenteral nutrition protocols. Hospitals also favor the format because placement is less costly than for dual-lumen alternatives. Single-lumen designs remain suitable when a patient needs one treatment stream at a time. This makes them practical for large public hospital procurement programs. Their established clinical use supports continued demand through 2031. The segment also benefits from staff familiarity with access, flushing, and routine maintenance. Suppliers with dependable standard products can remain relevant even as more specialized formats grow.

Double-Lumen Ports are forecast to grow at a CAGR of 9.89% through 2032. Growth is associated with complex hematologic malignancy treatment that requires blood product transfusion and medication delivery during the same clinical session. Two access channels can reduce the need for separate vascular access procedures. This can be valuable where multi-drug regimens are administered under time constraints. The other category includes valved ports with built-in anti-reflux features. These products are gaining attention in home infusion settings where reduced maintenance needs can have clinical and economic value. ECG-guided intracavitary tip confirmation is also emerging as a radiation-free alternative to fluoroscopy. The approach may widen placement options for ambulatory oncology centers that do not have interventional radiology infrastructure.

Standard implantable ports represented 48.25% of 2026 revenue, making them the largest format in the implantable Ports market size for port type. They are widely used in hospital oncology and nutrition programs. Standard designs serve patients who need dependable long-duration vascular access but do not require high-pressure contrast injection. Their broad availability supports use across health systems with different levels of procedural capacity. The format remains the routine choice for many chemotherapy administrations. Procurement teams can also evaluate standard products on durability, ease of placement, and maintenance requirements. This preserves their role in both mature and developing healthcare markets. Cost sensitivity is likely to sustain demand for this established option.

Power-Injectable implantable ports are forecast to grow at a CAGR of 10.35% through 2032. These ports can support high-pressure contrast injection of up to 5 mL per second through a standard Huber needle. This can avoid a separate intravenous access step during contrast-enhanced CT imaging. The functionality is relevant because CT is used for tumor staging and response assessment. Low-profile versions can be useful for patients with limited subcutaneous tissue. MRI-compatible ports serve a separate group of long-term surveillance and pediatric oncology patients. The supplied RD cited 2025 FDA clearances for updated power-injectable and low-profile product families. These developments indicate continued competition around imaging compatibility and broader use across oncology workflows.

Complete Report Scope:

  • By Product Type
    • Single-Lumen Implantable Ports
    • Double-Lumen Implantable Ports
    • Others
  • By Port Type
    • Standard Implantable Ports
    • Power-Injectable Implantable Ports
    • MRI-Compatible Implantable Ports
    • Others
  • By Material
    • Titanium
    • Polyurethane and Polymer
    • Silicone
    • Others
  • By Application
    • Chemotherapy and Oncology Delivery
    • Blood Transfusion and Fluid Resuscitation
    • Total Parenteral Nutrition
    • Long-Term Antibiotic and Anti-Infective Therapy
    • Others
  • By End User
    • Hospitals and Acute Care Facilities
    • Ambulatory Surgical Centers
    • Specialty Oncology Clinics
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 38.26% of global revenue in 2026, which gave the region the leading implantable ports market share. Mature oncology infrastructure and broad outpatient reimbursement supported demand for implanted vascular access. The United States led the regional use of advanced power-injectable and low-profile formats. Expansion of home-based anti-infective therapy reimbursement is shifting some placements from inpatient care to community settings. This favors devices suited to ongoing outpatient maintenance. Providers also face closer scrutiny of catheter material and clinical evidence. In 2026, AngioDynamics reported litigation related to certain port catheter materials in its fiscal-year results. The issue may increase attention to coated products and documented post-market performance.

Europe is the second-largest regional area in the supply of implantable ports. Germany, France, the United Kingdom, and Italy form the main demand base. France’s day-case oncology network supports the use of ports for ambulatory chemotherapy. Germany and the United Kingdom add demand through aging populations and outpatient antibiotic treatment. B. Braun reported EUR 584 million in research and development expenditure for 2025, an 11% increase from the prior year. The investment includes connected infusion and vascular access innovation. EU Medical Device Regulation requirements for Class IIb implantable devices require sustained clinical follow-up. This increases the evidence burden for new entrants and supports established manufacturers with existing clinical data systems.

Asia-Pacific is forecast to grow at a CAGR of 12.63% through 2032, the highest regional rate in the implantable ports market. China is the largest regional country and recorded 342,000 port implantation procedures in 2026. Oncology indications accounted for 68.5% of these placements. Demand was concentrated in tier-1 and tier-2 hospital oncology departments. Volume-based procurement policies are reducing prices for standard ports and supporting local manufacturers with domestic supply chains. India has strong growth potential as private hospital oncology capacity expands and public initiatives improve cancer treatment access in tier-2 and tier-3 cities. The Middle East, Africa, and South America add demand for cost-effective standard devices. Limited reimbursement and shortages of trained interventional teams restrict wider adoption of premium MRI-compatible and power-injectable formats outside leading private institutions.


List of Companies Covered in this Report:

  • AngioDynamics
  • Argon Medical Devices
  • B. Braun
  • Baxter
  • Beckton Dickinson
  • Cook Incorporated
  • Districlass Médical
  • Fresenius
  • ICU Medical
  • Linhua Medical
  • Medical Components Inc.
  • Medtronic
  • Merit Medical Systems
  • Nipro
  • PakuMed medical products GmbH
  • PFM Medical AG
  • Poly Medicure
  • Sophysa SA
  • Teleflex
  • Terumo
  • Vygon

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cancer Incidence and Chemotherapy Administration
4.2.2 Growing Geriatric and Chronic-Disease Treatment Burden
4.2.3 Increasing Preference for Long-Term, Fully Implanted Vascular Access
4.2.4 Expansion of Outpatient and Home-Based Infusion Therapy
4.2.5 Port Standardization in Pediatric and Difficult-Access Care
4.2.6 Device Differentiation Through Antithrombogenic and Antimicrobial Materials
4.3 Market Restraints
4.3.1 Port- and Catheter-Related Infection and Thrombosis
4.3.2 Surgical Implantation Cost and Procedure Complexity
4.3.3 Fragmented Maintenance Protocols and Home-Care Capability Gaps
4.3.4 Competition from PICCs and External Catheters
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Product Type
5.1.1 Single-Lumen Implantable Ports
5.1.2 Double-Lumen Implantable Ports
5.1.3 Others
5.2 By Port Type
5.2.1 Standard Implantable Ports
5.2.2 Power-Injectable Implantable Ports
5.2.3 MRI-Compatible Implantable Ports
5.2.4 Others
5.3 By Material
5.3.1 Titanium
5.3.2 Polyurethane and Polymer
5.3.3 Silicone
5.3.4 Others
5.4 By Application
5.4.1 Chemotherapy and Oncology Delivery
5.4.2 Blood Transfusion and Fluid Resuscitation
5.4.3 Total Parenteral Nutrition
5.4.4 Long-Term Antibiotic and Anti-Infective Therapy
5.4.5 Others
5.5 By End User
5.5.1 Hospitals and Acute Care Facilities
5.5.2 Ambulatory Surgical Centers
5.5.3 Specialty Oncology Clinics
5.5.4 Others
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 India
5.6.3.3 Japan
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
6.3.1 AngioDynamics Inc.
6.3.2 Argon Medical Devices Inc.
6.3.3 B. Braun Melsungen AG
6.3.4 Baxter International Inc.
6.3.5 Becton, Dickinson and Company
6.3.6 Cook Incorporated
6.3.7 Districlass Médical
6.3.8 Fresenius SE & Co. KGaA
6.3.9 ICU Medical Inc.
6.3.10 Linhua Medical
6.3.11 Medical Components Inc.
6.3.12 Medtronic plc
6.3.13 Merit Medical Systems Inc.
6.3.14 Nipro Corporation
6.3.15 PakuMed medical products GmbH
6.3.16 PFM Medical AG
6.3.17 Poly Medicure Limited
6.3.18 Sophysa SA
6.3.19 Teleflex Incorporated
6.3.20 Terumo Corporation
6.3.21 Vygon SA
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AngioDynamics Inc.
  • Argon Medical Devices Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cook Incorporated
  • Districlass Médical
  • Fresenius SE & Co. KGaA
  • ICU Medical Inc.
  • Linhua Medical
  • Medical Components Inc.
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Nipro Corporation
  • PakuMed medical products GmbH
  • PFM Medical AG
  • Poly Medicure Limited
  • Sophysa SA
  • Teleflex Incorporated
  • Terumo Corporation
  • Vygon SA